NVIDIA launches Jetson Thor robotics computers for physical AI systems
On Monday, Stifel analysts maintained a Hold rating on Medtronic , Inc. (NYSE:MDT) shares, with a price target set at $87.00. The medical device giant, currently valued at $112.39 billion, trades near its InvestingPro Fair Value with a P/E ratio of 26.7. The firm’s commentary focused on the long-term data concerning Medtronic’s Transcatheter Aortic Valve Replacement (TAVR) technology. Analysts observed that while the TAVR data continues to show non-inferiority when compared to traditional surgery, there is a noticeable narrowing in the performance gap between the two methods.
The TAVR technology, which allows for valve replacement without the need for open-heart surgery, has been a significant area of interest for both the medical community and investors. The latest data, reflecting a five-year period, suggests that the TAVR approach is holding up in terms of efficacy when set against surgical alternatives. According to InvestingPro, Medtronic maintains a GOOD financial health score, with strong cash flows and 49 consecutive years of dividend payments, currently yielding 3.2%.
Medtronic has been monitoring the performance of its TAVR system over several years to ensure that it remains a viable option for patients requiring aortic valve replacement. The recent observations by Stifel analysts indicate that while the TAVR system is still a competitive option, the difference in outcomes between it and surgical procedures has become less pronounced over time.
The price target of $87.00 reflects Stifel’s assessment of Medtronic’s current valuation, considering the latest clinical data. Medtronic’s stock performance and investor sentiment are often influenced by such evaluations and the implications they may have for the company’s product portfolio and market position.
As the market continues to assess the long-term prospects of Medtronic’s TAVR technology, Stifel’s reiteration of their Hold rating and price target provides a snapshot of the firm’s current view on the stock’s potential. Medtronic, as a leading medical device company, continues to invest in research and development to maintain its position in the competitive landscape of medical technology.
In other recent news, Medtronic reported its fiscal third-quarter 2025 earnings, with revenue reaching $8.29 billion, slightly missing the consensus estimate of $8.33 billion. The company’s earnings per share (EPS) of $1.39 exceeded expectations, surpassing the forecasted $1.36. Citi analysts upgraded Medtronic’s stock rating from Neutral to Buy, raising the price target to $104, citing growth prospects in the Cardiac Ablation Solutions segment, which saw a 22% increase year-over-year. UBS also adjusted its price target for Medtronic to $95 while maintaining a Neutral rating, reflecting a belief that recent share price weakness may have been overstated.
Additionally, Medtronic received FDA approval for its BrainSense™ Adaptive deep brain stimulation system, which offers personalized treatment for Parkinson’s disease by adjusting therapy in real-time. This innovative technology is expected to enhance the precision of treatment and expand Medtronic’s neuromodulation offerings. Stifel analysts maintained a Hold rating with a price target of $87, noting the company’s slight revenue shortfall but expressing confidence in Medtronic’s core business strength.
Medtronic’s Investor Relations highlighted the company’s Long Range Plan, aiming for mid-single-digit top-line growth and faster bottom-line growth. The firm is also optimistic about its renal denervation technology, awaiting a National Coverage Determination from CMS, which could further bolster its growth trajectory. These developments reflect Medtronic’s ongoing efforts to innovate and expand its market presence across various healthcare segments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.